| Literature DB >> 33815869 |
Stefano Rizza1, Pasquale Morabito1, Livia De Meo1, Alessio Farcomeni2, Giulia Testorio1, Marina Cardellini1, Marta Ballanti1, Francesca Davato1, Chiara Pecchioli1, Giovanni Di Cola1, Maria Mavilio1, Massimo Federici1.
Abstract
The multidimensional prognostic index (MPI) is a sensitive and specific prognosis estimation tool that accurately predicts all-cause mortality in frail older patients. It has been validated to assess the risk of 1-month to 2-year mortality in frail older patients during hospitalization and after hospital discharge. However, whether the MPI is a valid prognostic tool for follow-up periods of different lengths remains to be validated. To this end, we followed up 80 hospitalized patients (female=37, male 43) at least 75 years of age (mean age=82.6±4.4, range=75-94 years) to assess the 3-month all-cause mortality (mean follow-up=61.0 ± 31.7 months [range 4-90 days]). Accordingly, patients were subdivided into low (MPI-1, score 0-0.33), moderate (MPI-2, score 0.34-0.66) and high (MPI-3, score 0.67-1) mortality risk classes. Moreover, baseline biochemical, inflammatory and metabolic parameters, as well as anamnestic and clinical characteristics, were obtained. Although the MPI-3 score was significantly associated with 3-month all-cause mortality in univariate analysis (HR=5.79, 95%CI=1.77-18.92, p=0.004), a multivariate model indicated that only low albumin (HR=0.33, 95%CI=0.16-0.68, p=0.003) and high IL6 (HR=1.01, 95%CI=1.00-1.02, p=0.010) levels were significantly associated with 3-month all-cause mortality. In conclusion, we suggest that measurement of IL6 as well as albumin, rather than the MPI score, may help in providing tailored therapeutic interventions to decrease short term mortality in older hospitalized individuals. copyright:Entities:
Keywords: IL6; MPI; albumin; elderly; frailty; in-hospital mortality
Year: 2021 PMID: 33815869 PMCID: PMC7990358 DOI: 10.14336/AD.2020.0713
Source DB: PubMed Journal: Aging Dis ISSN: 2152-5250 Impact factor: 6.745